Biotech startup Lamark Biotech, headquartered in India, has raised ₹6.5 crore in Pre-Series A funding from IAN Group and BioAngels. The company focuses on developing thermostable insulin and biologic solutions aimed at improving accessibility and affordability of diabetes treatment globally.

The funds will accelerate R&D activities, scale up pilot production, and strengthen IP portfolios. Lamark Biotech’s work aligns with the growing need for affordable and stable insulin solutions, especially in tropical climates where cold-chain dependency limits access.

This seed round demonstrates the rising investor appetite for innovative healthcare solutions addressing critical unmet medical needs in emerging markets.